» Articles » PMID: 18242221

Hepatic Fatty Acid Transporter Cd36 is a Common Target of LXR, PXR, and PPARgamma in Promoting Steatosis

Overview
Specialty Gastroenterology
Date 2008 Feb 5
PMID 18242221
Citations 275
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Liver X receptor (LXR) is known to promote hepatic lipogenesis by activating the lipogenic transcriptional factor sterol regulatory element-binding protein (Srebp). Pregnane X receptor (PXR), a previously known "xenobiotic receptor," could mediate a Srebp-independent lipogenic pathway by activating the free fatty acid uptake transporter Cd36. The goal of this study is to investigate further the role of Cd36 in hepatic steatosis.

Methods: Wild-type, LXR transgenic, PXR transgenic, and Cd36 null mice were used to study the regulation of Cd36 and other hepatic lipogenic genes and the implication of this regulation in hepatic steatosis. Promoter sequences of Cd36 and peroxisome proliferator-activated receptor (PPAR) gamma were cloned, and their respective regulation by LXR and PXR was investigated by combinations of receptor-DNA binding and reporter gene assays.

Results: We showed that genetic (transgene) or pharmacologic (ligands) activation of LXR induced Cd36. Promoter analysis established Cd36 as a novel transcription target of LXRalpha. Moreover, the hepatic steatosis induced by LXR agonists was largely abolished in Cd36 null mice. We also showed that PPARgamma, a positive regulator of Cd36, is a transcriptional target of PXR, suggesting that PXR can regulate Cd36 directly or through its activation of PPARgamma. Interestingly, both LXR-mediated Cd36 regulation and PXR-mediated PPARgamma regulation are liver specific.

Conclusions: We conclude that Cd36 is a shared target of LXR, PXR, and PPARgamma. The network of CD36 regulation by LXR, PXR, and PPARgamma establishes this free fatty acid transporter as a common target of orphan nuclear receptors in their mediation of lipid homeostasis.

Citing Articles

New insights in the pathogenesis of alcohol-related liver disease: The metabolic, immunologic, and neurologic pathways.

Ryu T, Kim K, Choi S, Chung K, Jeong W Liver Res. 2025; 7(1):1-8.

PMID: 39959703 PMC: 11791844. DOI: 10.1016/j.livres.2022.09.004.


Deciphering the Role of CD36 in Gestational Diabetes Mellitus: Linking Fatty Acid Metabolism and Inflammation in Disease Pathogenesis.

Huang L, Zhang T, Zhu Y, Lai X, Tao H, Xing Y J Inflamm Res. 2025; 18:1575-1588.

PMID: 39925938 PMC: 11806725. DOI: 10.2147/JIR.S502314.


The hypolipidemic effect of MI-883, the combined CAR agonist/ PXR antagonist, in diet-induced hypercholesterolemia model.

Dusek J, Mejdrova I, Dohnalova K, Smutny T, Chalupsky K, Krutakova M Nat Commun. 2025; 16(1):1418.

PMID: 39915454 PMC: 11802874. DOI: 10.1038/s41467-025-56642-y.


Transcription factors, metabolic dysfunction-associated fatty liver disease, and therapeutic implications.

Hu S, Ai Y, Hu C, Cassim Bawa F, Xu Y Genes Dis. 2025; 12(3):101372.

PMID: 39911797 PMC: 11795806. DOI: 10.1016/j.gendis.2024.101372.


The fungicide propiconazole induces hepatic steatosis and activates PXR in a mouse model of diet-induced obesity.

Attema B, Kummu O, Krutakova M, Pavek P, Hakkola J, Hooiveld G Arch Toxicol. 2024; 99(3):1203-1221.

PMID: 39718591 DOI: 10.1007/s00204-024-03942-9.